Pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of all
pancreatic tumours, is a devastating malignancy with an extremely poor prognosis, as …

Background Methodological limitations of prior studies have prevented progress in the
treatment of patients with borderline resectable pancreatic adenocarcinoma. Shortcomings …

Importance National guidelines endorse treatment with neoadjuvant therapy for borderline
resectable pancreatic ductal adenocarcinoma (PDAC), but the optimal strategy remains …

BACKGROUND: Experience with preoperative therapy for other cancers has led to an
assumption that borderline resectable pancreatic cancers can be converted to resectable …

Background Laparoscopic pancreaticoduodenectomy (LPD) is gaining momentum, but there
is still uncertainty regarding its safety, reproducibility, and oncologic appropriateness. This …

Pancreatic cancer is the fourth leading cause of cancer death in the United States. While
surgical resection remains the only curative option, more than 80% of patients present with …

The poors outcomes associated with pancreatic cancer clearly reflect the advanced stage of
disease at diagnosis for most patients. Through this lens, it is easy to lose sight of the fact …

BACKGROUND: To evaluate the accuracy of MDCT for determination of resectability R0
after neoadjuvant therapy in patients with pancreatic head adenocarcinoma locally …

Introduction: Vascular resection remains a subject of debate in the management of
Pancreatic Ductal Adenocarcinoma (PDAC). These French recommendations were drafted …

Purpose To prospectively evaluate the utility of computed tomography (CT) for determination
of tumor response and prediction of resectability after neoadjuvant combined chemotherapy …